| Revista: | The brazilian journal of infectious diseases |
| Base de datos: | PERIÓDICA |
| Número de sistema: | 000291030 |
| ISSN: | 1413-8670 |
| Autores: | Parise, E1 Cheinquer, H2 Crespo, D3 Meirelles, A4 Martinelli, A5 Sette, H6 Gallizi, J7 Silva, R8 Lacet, C9 Correa, E10 Cotrim, H11 Fonseca, J12 Parana, R Spinelli, V13 Amorim, W14 Tatsch, F15 Pessoa, M16 |
| Instituciones: | 1Universidade de Sao Paulo, Sao Paulo. Brasil 2Santa Casa de Misericordia, Servico de Gastroenterologia, Porto Alegre, Rio Grande do Sul. Brasil 3Universidade Federal do Para, Belem, Para. Brasil 4Universidade Federal de Juiz de Fora, Juiz de Fora, Minas Gerais. Brasil 5Universidade de Sao Paulo, Faculdade de Medicina de Ribeirao Preto, Ribeirao Preto, Sao Paulo. Brasil 6Instituto Emilio Ribas, Sao Paulo. Brasil 7Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerais. Brasil 8Universidade de Sao Paulo, Faculdade de Medicina de Sao Jose do Rio Preto, Sao Jose do Rio Preto, Sao Paulo. Brasil 9Universidade Federal de Alagoas, Maceio, Alagoas. Brasil 10Universidade Federal de Santa Catarina, Florianopolis, Santa Catarina. Brasil 11Universidade Federal da Bahia, Salvador, Bahia. Brasil 12Fundacao de Medicina Tropical do Amazonas, Manaus, Amazonas. Brasil 13Hospital Oswaldo Cruz, Recife, Pernambuco. Brasil 14Universidade Federal da Paraiba, Joao Pessoa, Paraiba. Brasil 15Roche Brazil, Rio de Janeiro. Brasil 16Instituto Emilio Ribas, Sao Paulo. Brasil |
| Año: | 2006 |
| Periodo: | Feb |
| Volumen: | 10 |
| Número: | 1 |
| Paginación: | 11-16 |
| País: | Brasil |
| Idioma: | Inglés |
| Tipo de documento: | Artículo |
| Enfoque: | Caso clínico |
| Resumen en inglés | Peginterferon alfa plus ribavirin is currently the treatment of choice for chronic hepatitis C. Peginterferon alfa-2a (40KD) plus ribavirin has given an overall sustained virological response of 18% in F3/F4 previous nonresponder US patients. We evaluated the effectiveness of peginterferon alfa-2a (40KD) plus ribavirin in Brazilian patients who were relapsers or nonresponders to previous interferon-based therapy. One-hundred-thirty-four patients with biopsy-proven chronic hepatitis C, HCV RNA positive, elevated ALT and who were either relapsers (n=37) or nonresponders (n=97) to at least 24 weeks of conventional interferon/ribavirin therapy were retreated with peginterferon alfa-2a (40KD) 180mg/qw and ribavirin 800mg bid for 48 weeks. Efficacy was assessed as virological response (defined as undetectable HCV RNA) at the end of treatment (EoT) and at the end of follow-up (SVR - Sustained Virological Response). Safety assessments consisted of clinical and laboratory evaluations. In the patient sample, 72% were genotype 1 and 34% were cirrhotic. In an intention-to-treat analysis, relapser patients showed 78% EoT response and 51% SVR. Nonresponders showed 57% EoT response and 26% SVR. Positive predictive factors of SVR were non-1 genotype and relapser state. Six percent of the patients interrupted treatment because of adverse events and 45% had dose reduction (mainly associated with leucopenia and anemia). Brazilian patient relapsers and nonresponders to conventional interferon and ribavirin treatment can achieve a sustained virological |
| Disciplinas: | Medicina, Química |
| Palabras clave: | Terapéutica y rehabilitación, Bioquímica, Química farmacéutica, Peginterferon alfa-2a, Ribavirina, Hepatitis C, Seguridad, Eficacia |
| Keyword: | Medicine, Chemistry, Therapeutics and rehabilitation, Biochemistry, Medicinal chemistry, Peginterferon alpha-2a, Ribavirin, Hepatitis C, Safety, Efficacy |
| Texto completo: | Texto completo (Ver HTML) |
